Centro Investigación en Educación Superior

Mesenchymal stem cell therapy for doxorubicin cardiomyopathy: hopes and fears

CATEGORÍA(S): , , , , , , .
AUTOR(ES): Fernando Ezquer / Jaime Gutiérrez / Marcelo Ezquer / Christian Caglevic / Helio C Salgado / Sebastián D Calligaris.
Licencia Creative Commons Reconocimiento CC BY. Esta obra está bajo una Licencia Creative Commons Reconocimiento CC BY 4.0 Internacional.

Chemotherapy has made an essential contribution to cancer treatment in recent decades despite its adverse effects. As cancer survivors have increased, concern about ex-patient lifespan has become more important too. Doxorubicin is an effective anti-neoplastic drug that produces a cardiotoxic effect. Cancer survivors who received doxorubicin became more vulnerable to cardiac disease than the normal population did. Many efforts have been made to prevent cardiac toxicity in patients with cancer. However, current therapies cannot guarantee permanent cardiac protection. One of their main limitations is that they do not promote myocardium regeneration. In this review, we summarize and discuss the promising use of mesenchymal stem cells for cardioprotection or cardio-regeneration therapies and consider their regenerative potential without leaving aside their controversial effects on tumor progression.

Documentos relacionados

Centro Investigación en Educación Superior

Evaluación preoperatoria y predictores de morbimortalidad en resección de cáncer de pulmón

Surgical resection of lung cancer, the only available curative option today, is strongly associated with mortality. The goal during the […]

Centro Investigación en Educación Superior

Treating substance abuse is not enough: Comorbidities in consecutively admitted female prisoners

Several studies have pointed to high rates of substance use disorders among female prisoners. The present study aimed to assess […]

Saltar a la barra de herramientas